Shanghai, China, August 22, 2022 – The Financial Association and the “Science and Technology Innovation Board Daily” recently held an online summit in conjunction with the third anniversary of the founding of the Sci-tech Innovation Board, where they jointly released the “Science and Technology Innovation Board’s Third Anniversary Selection” list. Asieris, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, has been included in the list of 2022’s Most Innovative Companies on the STAR Market.
Led by the Shanghai Printing Industry Group, the summit, which hosted by the Jiemian Financial Association and sponsored by the Science and Technology Innovation Board Daily, featured the theme “Strong Drive and New Tech Engines”. Mr. Yu Xiaoliang, Secretary of the Board of Directors at Asieris, was invited to attend the summit’s “Dialogue with Tech Leaders: Biomedicine” roundtable forum, where he discussed current challenges and advancements of domestic innovative drug development.
“There should be more incentives in place for pharmaceutical companies which are truly committed to innovation.” Mr. Yu Xiaoliang highlighted, “Asieris’ main focus lies on genitourinary tumors and other major diseases, and it is an enterprise that also targets sub-specialties. Non-muscle invasive bladder cancer (NMIBC), which is among the indications targeted by APL-1202 (one of the company’s core products) is no less important than other more common cancer types, but there is currently no ideal treatment option for patients with recurrent NMIBC. Additionally, as this specific niche is still relatively unsaturated, it was easier to establish advantages in terms of R&D and commercialization.”
The selection process for the list covers more than 400 companies on the Science and Technology Innovation Board. Selection is based on stringent criteria such as innovative capabilities and growth rate, proportion of R&D investment, introduction of talent, intellectual property rights, as well as invention and innovation. Secondary criteria include the number of patents between 2019-2021. Twenty companies with outstanding innovative capabilities were eventually shortlisted based on these criteria and Asieris is proud to be listed among them and to be recognised for the strength of its innovative R&D.
Asieris Pharmaceuticals is the first innovative drug company to be listed on the Science and Technology Innovation Board this year, and is committed to being deeply involved in the genitourinary field, gaining insight into and exploring unmet clinical needs, and actively discovering innovative solutions for integrated diagnosis and treatment. At present, there are 12 research projects linked to 9 major innovative products ongoing. Among them, the two core products of VesiqueTM (APL-1202) and Cevira® (APL-1702) are aimed at bladder cancer and cervical precancerous lesions, respectively, therapeutic areas where are currently unmet medical needs, globally. The corresponding 3 studies are currently in Phase III or pivotal clinical trials. In the future, the company will continue to explore the field of genitourinary tumours, steadily advance various research and development pipelines, and promote innovative solutions to benefit more Chinese and global patients.
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health and help people live a more dignified life. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.
Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.